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Differential distribution of the vasopressin V2 receptor along
the rat nephron during renal ontogeny and maturation.
Background. Ontogeny and cellular distribution of vaso-
pressin receptors in the kidney are key factors determining
the role of vasopressin in renal physiology. Expression of va-
sopressin V2 receptor (V2R) mRNA and the immunoreactive
protein in rat kidney were investigated.
Methods. An antiserum directed to epitope TLD25 of the
rat V2R sequence was characterized by Western blotting. Ex-
pression of V2R mRNA was assessed by reverse transcription-
polymerase chain reaction (RT-PCR), and on protein level by
immunohistochemistry.
Results. Specificity of the antiserum was documented by
Western blots from cells expressing a fusion protein of V2R and
GFP. Using lysates of rat kidney and of native cell lines express-
ing V2R but not V1R, our antiserum to peptide TLD25 revealed
a major band of 55 kD corresponding to the monomeric form
of V2R, and a band of 110 kD most likely representing the ho-
modimeric form of the receptor. This highly specific antiserum
allowed us to localize the V2R in thick ascending limbs, dis-
tal convoluted and connecting tubules, and in collecting ducts.
During ontogeny, immunoreactivity was first observed at the
luminal membrane on prenatal day 20, emerging at the basolat-
eral side from postnatal day 5 on. RT-PCR demonstrated V2R
transcripts from prenatal day 18 to gradually increasing there-
after.
Conclusion. Expression of V2R is first detectable in the late
embryonic stage of rat ontogeny starting from day E18 and
gradually increasing with kidney maturation. In the adult kid-
ney, V2R is differentially distributed in the various nephron
segments.
Vasopressin (AVP) has many actions in the kidney,
the most conspicuous being the reabsorption of wa-
ter and electrolytes. These actions are primarily me-
diated through V1 receptors (V1R) and V2 receptors
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ontogeny, connecting tubule.
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(V2R) belonging to the superfamily of G protein–coupled
receptors characterized by 7 transmembrane-spanning
regions. V1R activates through Gq/11 the effector
enzyme phospholipase C, catalyzing the breakdown of
phosphatidylinositol-4,5-bisphosphate (PIP2) into the
second messengers diacylglycerol (DAG) and inositol
triphosphate (IP3), which in turn stimulate protein ki-
nase C and induce the release of Ca2+ from intracellular
stores, respectively. The V2R activates through Gs, the
effector adenylate cyclase, thereby elevating intracellu-
lar cAMP levels, which in turn activate cAMP-dependent
protein kinases that phosphorylate their multiple down-
stream targets, including water channels [1].
The cDNAs for rat V1R, V2R, and V3R have been
cloned. The deduced amino acid sequences predict for
proteins of 44.2 kD containing 2 potential N-glycosylation
sites for V1R [2], 40.5 kD and a single potential N-
glycosylation site for V2R [3], and 46.6 kD holding a sin-
gle N-glycosylation site for V3R [4]. Knowing the exact
localization of AVP receptors in the kidney is critical to
fully understand the functional role of vasopressin in kid-
ney physiology and pathophysiology. We have previously
explored the renal distribution of V1R using antirecep-
tor antibodies and found it to be located in connecting
tubules, collecting ducts, and in the thick ascending limb
[5, 6]. Controversy still exists regarding the precise local-
ization and site(s) of action for V2R in the kidney. Several
approaches to identify the tissue distribution of V2R pro-
tein and its mRNA in the kidney have been employed,
such as receptor targeting by radio- or fluorophor-labeled
ligands, or reverse transcription-polymerase chain re-
action (RT-PCR) in isolated nephron segments [7].
However, these techniques have failed to reveal the ex-
act cellular and subcellular localization of the V2R in this
organ. Early studies using in situ hybridization demon-
strated the expression of V2R mRNA in cells of the de-
veloping medullary and cortical collecting ducts in the
kidney of 16- and 19-day-old embryos [8]. Consistent with
these findings, the earliest AVP binding sites were re-
ported in the kidney of 19-day-old embryos [9].
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Using an antipeptide antiserum, we have studied the
ontogeny of immunoreactive V2R and its cognate mRNA
in the developing rat nephron, and analyzed their differ-
ential tissue distribution in the adult rat kidney. By using
specific tubule markers we provide evidence for the local-
ization of the V2R protein in thick ascending limbs, distal
convoluted and connecting tubules, and collecting ducts,
and demonstrate that immunoreactive V2R is exposed
both on basolateral and luminal cell membranes.
METHODS
Animals and tissue collection
Adult female Sprague-Dawley rats weighing 200 to
250 g were housed in a light- and temperature-controlled
room with free access to chow and water. Vaginal smears
were taken daily. Rats presenting a regular 4-day cycle
were randomly caged with fertile males on the night of
proestrus. The presence of sperm in the vaginal smear
defined day 1 of pregnancy.
Four to 6 animals were sacrificed between 10:00 h and
12:00 h at days 18 (E18), 20 (E20), and 21 (E21) of preg-
nancy and at days 1, 3, 5, 12, 22, 30, 60, and 120 of postnatal
life (P1, P3, etc.). Rats were anesthetized with ether and
the kidneys extracted and frozen directly in liquid nitro-
gen, or small slices of tissue (1.5 to 2 mm thick) were
fixed by immersion in 4% formol-saline, Bouin’s fluid,
or periodate-lysine-paraformaldehyde fixative [10]. Sam-
ples were immersed in the fixative for 24 to 48 hours at
room temperature. In some cases, rats were anesthetized
with ether and perfused in a retrograde fashion through
the descending aorta, first with phosphate-buffered saline
(PBS) and then with periodate-lysine-paraformaldehyde.
Afterward, kidney slices were post-fixed in the same fix-
ative for 6 hours. Samples were dehydrated in a graded
series of ethanol and embedded in Histosec (Merck;
Darmstadt, Germany). Four to 5 sections (5 lm thick)
were analyzed from each animal; these were mounted on
glass slides precoated with polylysine or gelatine (Sigma-
Aldrich, St. Louis, MO, USA).
Production of antipeptide antibodies to V2R
Four peptide segments of 24 to 31 residues in length
were selected from the predicted amino acid sequence
of rat V2R [3] by the criteria of hydrophilicity, poten-
tial antigenicity, relative location within the sequence,
relative orientation to the membrane, and lack of se-
quence identity with other types of vasopressin recep-
tors. The corresponding synthetic peptides were directly
used for immunization in rabbits, or previously cou-
pled to keyhole limpet hemocyanin via the 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) method. An
indirect enzyme-linked immunosorbent assay (ELISA)
with the V2R peptide and unrelated peptides (negative
controls) as the capture antigens was employed to follow
the titer of antipeptide sera and to establish their speci-
ficity [11]. Antipeptide antibodies were also character-
ized by Western blotting with membranes prepared from
cells stably transfected with GFP-tagged V2R or cell lines
expressing V1R (i.e., A-10 smooth muscle cells from rat
aorta), or expressing V2R (i.e., LLC-PK1 cells from nor-
mal pig kidney and IMCD-3 from mouse inner medullary
collecting ducts). The best antipeptide antiserum was ob-
tained with a peptide directed against the second in-
tracellular loop designated as TLD25, whose sequence
was NH2-TLDRHRAICRPMLAYRHGGGARWNR-
COOH. This antiserum, designated AS382, was used for
all following studies.
Vector constructions
Wild-type V2R cDNA was amplified by RT-PCR from
rat kidney total RNA and subcloned into the pEGFP N1
vector (BD Biosciences, Clontech, San Jose, CA, USA).
The stop codon of the V2R cDNA was removed and
placed in frame with the GFP cDNA. The sequence fi-
delity of the V2R-GFP construct was verified by DNA
sequencing.
Cell culture and transfections
A-10 (ATCC CRL 1476), IMCD-3 (ATCC CRL 2123),
and LLC-PK1 cells (ATCC CL 101) were cultured to
subconfluency on 35 mm dishes in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal calf
serum, 100 U/mL penicillin, 100 lg/mL streptomycin, and
0.25 lg/mL amphotericin B. MDCK cells (ATCC CCL 34)
were stably transfected with 2 lg of GFP-tagged V2R us-
ing FuGENE 6 (Roche Diagnostic Co., Indianapolis, IN,
USA), and after 72 hours, cells expressing the receptor
were selected using 700 lg/mL Geneticin (G418). After
3 weeks, single colonies were transferred to 35 mm plates.
Membrane preparation
A10, IMCD-3, LLC-PK1, stably transfected MDCK
cells and kidney from adult rats were homogenized with
5 mmol/L Tris-HCl buffer, pH 7.4, containing 1 mmol/L
EDTA, 1 mmol/L PMSF, 1 lg/mL leupeptin, 1 lg/mL
aprotinin, 5 lg/mL pepstatin (lysis buffer). The ho-
mogenate was centrifuged at 3000g for 5 minutes, and
the supernatant was centrifuged at 30,000g for 30 min-
utes. The resulting pellet was resuspended in lysis buffer
or in PBS containing 0.1 mmol/L PMSF.
Endoglycosidase H digestion
Membranes (300 lg) were solubilized in 900 lL of
radioimmune precipitation assay buffer (50 mmol/L
Tris-HCl, pH 7.4, 150 mmol/L NaCl, 0.1% SDS, 0.5%
sodium deoxycolate, 1% Nonidet P40, 10 mmol/L
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N-ethylmaleimide, 0.1 mmol/L PMSF, 5 mg/mL soybean
trypsin inhibitor, and 1 lg/mL leupeptin) for 12 hours at
4◦C and then centrifuged for 5 minutes at 16,000g. The
supernatant was incubated with 30 lL of wheat germ ag-
glutinin agarose slurry (Sigma) for 12 hours at 4◦C under
constant shaking. Wheat germ agglutinin-bound glyco-
proteins were digested with 10 mU of endoglycosidase H
(Calbiochem EMD Biosciences, Inc., La Jolla, CA, USA)
for 24 hours at 37◦C and the digested glycoproteins were
subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE).
Western blotting
Equal amount of protein (80 lg per lane) was loaded
on a 12.5% polyacrylamide gel including 0.1% SDS
and separated by electrophoresis at constant voltage for
3 hours. Proteins were electrotransferred onto nitrocel-
lulose filters in 0.05% SDS, 20 mmol/L Tris-glycine, and
20% methanol (transfer buffer). Filters were incubated
with the antibody to V2R diluted in 20 mmol/L Tris-
HCl, pH 7.6, 500 mmol/L NaCl, 0.05% Tween 20. Bound
immunoglobulins were detected with the alkaline phos-
phatase technique (Bio-Rad, Hercules, CA, USA), or by
the chemiluminiscence method (Pierce Biotechnology,
Inc., Rockford, IL, USA).
Immunostaining procedure
Sections prepared from embedded tissue were de-
waxed with xylene, rehydrated through a graded series
of ethanol, and treated with absolute methanol and 1%
hydrogen peroxide to block endogenous pseudoperoxi-
dase activity. After rinsing (3 × 5 min) in 50 mmol/L Tris-
HCl buffer, pH 7.8, the sections were incubated with anti-
TLD25 antibody diluted 1:200 in 50 mmol/L Tris-HCl, pH
7.8, containing 1% immunoglobulin-free bovine serum
albumin (BSA; Sigma). Bound antibodies were detected
using an avidin-biotin kit (LSAB+, Dako Co., Carpinte-
ria, CA, USA) following the manufacturer’s instructions.
All incubations were performed at 22◦C in a water bath
used as a humidifier chamber. Between incubations, the
sections were washed 3 times for 5 minutes each in Tris-
HCl, pH 7.8. Peroxidase activity was detected with 0.1%
(w/v) 3-3′-diaminobenzidine and 0.03% (v/v) hydrogen
peroxide for 5 minutes at room temperature. For cell lines
expressing V1R or V2R, bound primary antibodies were
detected by a F(ab’)2 fluorescein isothiocyanate(FITC)-
labeled antirabbit IgG (Dako Co.). To identify the type
of tubules expressing the V2R we used antibodies di-
rected against marker proteins [i.e., Tamm-Horsfall pro-
tein (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA) for the identfication of the thick ascending limb,
the Na+/Cl− cotransporter (Santa Cruz Biotechnology,
Inc.) for the distal convoluted tubule, aquaporin-2 (Santa
Cruz Biotechnology, Inc.) for collecting ducts, and urinary
kallikrein for connecting tubules]. The anti-kallikrein
strongly recognizes rK1 (“true” kallikrein), has a mod-
erated affinity for rK2 and rK7, and shows a weak
cross-reactivity with rK9 [12, 13]. Immunohistochemical
controls were prepared by application of the correspond-
ing preimmune sera, by omission of primary antibodies,
by their replacement with an unrelated antiserum, and/or
by preabsorption with a large molar excess of the cognate
peptide (50–100 lg/mL) used for immunization [12, 14].
Reverse transcription and polymerase chain reaction
Approximately 100 mg of whole kidney tissue from rats
of 18 and 20 days of gestational age and 1, 5, 22, 60 and
120 days after birth were used to prepared total RNA us-
ing Ultraspec (Biotecx Houston, TX, USA). The cDNAs
were synthesized using oligo-dT primers and SuperScript
II (Gibco BRL, Rockville, MD, USA). The mRNA ex-
pression was monitored by PCR using the method of the
primer-dropping [15]. The glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA was used as an
internal non-competitive standard to normalize the ex-
pression of V2R. Primers for the V2R were the 5′-TGCT
GTGACAGGTGTGTTAGGTCA-3′ (sense) and 5′-CC
ATGGTTCTGCAAATCGGG-3′ (antisense) which
should generate a fragment of 625 bp. For GAPDH,
5’-AGATCCACAACGATACATT-3′ (sense) and 5′-TC
CCTCAAGATTGTCAGCAA-3′ (antisense) producing
a fragment of 288 bp were used. The ratio of co-amplified
products was estimated during the exponential phase of
PCR. The PCR reaction mixture contained 50 pmol of
each primer pair for V2R and GAPDH, 1 mmol/L de-
oxynucleotides, 1 × Taq polymerase reaction buffer, 1.5
mmol/L MgCl2, and 2.5 U Taq polymerase. One fifth of
the PCR reactions were fractionated by electrophoresis
on a 1.6% agarose gel, stained with ethidium bromide,
and the bands were visualized in a UV transilluminator.
Data analysis
Densitometric analyses of gel digital images were done
using the Un-Scan-it gel software (Silk Scientific, Inc.,
Orem, UT, USA) and the relative mRNA level was nor-
malized by comparison to the GAPDH mRNA signal.
Comparisons between two means were made with ratio-
paired t test using SigmaStat (SPSS, Inc., Chicago, IL,
USA); values of P < 0.05 were considered significant.
RESULTS
Antibody production and characterization
To determine the specificity of antiserum AS382 raised
against peptide TLD25 present in the second intra-
cellular loop of V2R, we expressed in MDCK cells a
chimeric protein of GFP fused to the C-terminus of
V2R and probed lysates of the corresponding membrane
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Fig. 1. Identification of V2R in membranes from MDCK cells trans-
fected with GFP-tagged V2R. Western blotting of membranes from
MDCK cells non-transfected (−) or stably transfected with cDNA en-
coding V2R-GFP fusion protein (+), in the absence (−) or presence (+)
of tunicamycin (Tm). Anti-GFP (A) or anti-TLD25 (AS382) at 1:4000
(B) was used for immunodetection by the chemiluminescence method.
I, immature monomer; M, mature monomer; D, dimer. The figure is a
representative of 3 independent experiments.
preparations by Western blotting with anti-TLD25 or
anti-GFP as primary antibodies. Both anti-GFP and
anti-TLD25 showed immunoreactive bands of 60, 75
and 120 kD (Fig. 1A). Non-transfected MDCK cells
showed no bands. To determine whether some of this
heterogeneity was due to N-glycosylation of the re-
ceptor, MDCK cells expressing the GFP-tagged V2R
were treated with tunicamycin to inhibit N-glycosylation.
Western blots of the corresponding lysates showed a
major immunoreactive band of 50 kD and two minor
bands of 110 and 120 kD (Fig. 1A), suggesting that the
60 kD and 75 kD bands (monomer) and the 120 kD
band (dimer) observed in untreated cells likely repre-
sent differentially glycosylated forms of V2R-GFP [16,
17, 18]. Application of anti-TLD25 revealed a similar
band pattern for V2R-GFP-expressing cells, whereas
non-transfected cells were devoid of immunoreactive
bands (Fig. 1B). To further characterize anti-V2R, West-
ern blots of crude cell membranes prepared from cell
lines expressing a single type of vasopressin receptor
were done. Lysates of the membrane fractions from
LLC-PK1 and IMCD3 cells known to express V2R but
not V1R showed a dominant band of approximately
55 kD (Fig. 2A), as would be expected for a fully gly-
cosylated V2R protein, and two minor bands of 90 and
115 kD; at least one of them (115 kD) may represent the
dimeric form of the receptor, while no such bands were
seen for membranes prepared from A10 cells that exclu-
sively express V1R (Fig. 2A). In line with these observa-
tions, immunofluorescence showed immunoreactive V2R
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Fig. 2. Identification of V2R in cell lines and tissues by Western blot-
ting and immunofluorescence. (A) Western blotting of crude membrane
proteins (50 lg each) from A10, LLC-PK1, and IMCD3 cell lysates. (B)
Pull-down of glycosylated proteins present in the lysates of rat kid-
ney membrane fractions by wheat germ agglutinin agarose, followed
by treatment with Endo H or buffer (control) and Western blotting.
(C) Cell membranes prepared from rat liver. For specificity controls,
preimmune serum of the same rabbit used for AS382 production or anti-
TLD25 preabsorbed with a molar excess of peptide TLD25 were used
(C). Nitrocellulose filters were incubated with anti-TLD25 (AS382) at
1:100 (A) or 1:4000 (B, C), and bound immunoglobulins were visualized
by a secondary antibody conjugated to alkaline phosphatase (A), or by
the chemiluminescence method (B, C). I, immature monomer; M, ma-
ture monomer; D, dimer. For immunofluorescence, cells were permeabi-
lized with methanol, fixed with 4% paraformaldehyde, and immunos-
tained with anti-TLD25 at 1:200 and a fluorescein-labeled secondary
antibody (D). Magnification, ×500. Each figure is a representative of 3
independent experiments.
in LLC-PK1 and IMCD3 cells but not in A10 cells
(Fig. 2F). Immunoreactivity was mainly associated with
the cell membrane of LLC-PK1 and IMCD3 cells, al-
though some immunoreactive vesicles were also present
in the cytoplasm of these cells, which may represent Golgi
or transport vesicles en route to the plasma membrane.
Western blots of membranes prepared from rat kidney
showed two prominent bands of 50 and of 110 kD and a
minor one of 55 kD, whereas those from rat liver mem-
branes expressing V1aR failed to show immunoreactive
bands (Fig. 2B). To determine the glycosylation status of
the receptor, rat kidney membranes proteins were solu-
bilized, precipitated with wheat germ agglutinin-coupled
agarose, and bound glycoproteins were incubated with
endoglycosidase H (Endo H). Treatment with Endo H
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yielded a doublet of 40 and 45 kD, respectively, and bands
of 55 and 110 kD, while for the nontreated lysates, bands
of 50, 55, and 115 kD were observed (Fig. 2C). Com-
bined, these results suggest that in the native cells, the
55 kD band may represent the maturated receptor with
a complex-type of glycosylation, whereas the 50 kD
band may correspond to an intermediate high-mannose
form of the receptor, and the broad 115 kD band rep-
resenting the dimers of the 50/55 kD forms. Preabsorp-
tion of anti-TLD25 with a large molar excess of TLD25
peptide (Fig. 2D) prior to Western blotting or replace-
ment of anti-TLD25 with the cognate preimmune serum
(Fig. 2D) failed to produce specific bands, thus further
demonstrating the specificity of anti-TLD25; from here
on we refer to it as anti-V2R.
Distribution of V2R in the rat kidney
After characterization, our antiserum was used to an-
alyze the distinct expression of V2R in rat kidney sec-
tions (Fig. 3). A strong staining was seen in the cortex, in
the outer and inner stripes of the outer medulla, and in
the inner medulla. In the cortex, distal nephron segments
and collecting ducts of medullary rays were prominently
immunostained, whereas glomeruli and proximal convo-
luted tubules were virtually unstained (Fig. 3A, E, and F).
In the medulla, collecting ducts and thick ascending limbs
were immunolabeled (Fig. 3D). Sections processed under
the same conditions using the corresponding preimmune
serum were essentially free of staining (Fig. 3B), as were
controls in the absence of a primary antibody or after pre-
absorption with the cognate peptide TLD25 (Fig. 3C).
Higher magnification of immunoreactive distal con-
voluted tubules (Fig. 3E) and collecting ducts (Fig. 3F)
showed that immunostaining indicative of V2R was
present not only on basolateral membranes but also on
the luminal membranes of tubular cells. At the basolat-
eral side of these cells, the basal infoldings were clearly
demarcated by the anti-V2R antibody (Fig. 3E and F).
Furthermore, some cells showed a good amount of cy-
toplasmic granular immunostaining (Fig. 3E, F). At the
outer stripe of the outer medulla most of the immunore-
activity was also observed on both the basolateral and
the apical sides of the thick ascending limbs (Fig. 3D).
A strong immunoreaction was also observed inside the
cells, which probably reflect the protein passing through
the different intracellular compartment.
To identify the nephron segments reactive with V2R
antiserum, we immunostained consecutive serial sections
using the anti-V2R antibody and either an antiserum di-
rected to Tamm-Horsfall protein, (thick ascending limbs)
or to Na+/Cl− co-transporter (distal convoluted tubules),
or to rat urinary kallikrein (connecting tubules) or to
Aquaporin 2, (connecting tubules and collecting ducts).
This immunohistochemical approach confirmed that the
V2R is expressed in the thick ascending limb, distal con-
voluted tubules, connecting tubule cells and in collecting
ducts (Fig. 4). In addition, we detected immunoreactive
V2R in tubules of the renal cortex that did not expressed
aquaporin-2 or kallikrein, indicating that they may cor-
respond to distal convoluted tubules (Fig. 4). Controls
done as specified above were negative throughout (data
not shown).
Developmental changes of the V2R in the rat kidney
We probed for the expression of V2R by reverse
transcription-polymerase chain reaction (RT-PCR) by si-
multaneously using primers to amplify a 625 bp cDNA
fragment derived from the 5′end of rat V2R mRNA,
in combination with primers to amplify a 309 bp frag-
ment of the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) to normalize the reaction (Fig. 5A). In or-
der to validate the quantitative analysis of our result we
worked in the linear part of the exponential PCR reac-
tion (Fig. 5A). Expression of the V2R gene started at
embryonic day E18, increased almost linearly until post-
natal day P22, and reached a plateau afterwards for more
than 100 days until postnatal day P120 (Fig. 5B and C).
In contrast, GAPDH gene expression remained largely
stable during rat kidney maturation (Fig. 5B). To sub-
stantiate the mRNA findings on the protein level, we
did immunohistochemistry on tissue samples prepared
from the same kidney segments used for RT-PCR. Im-
munoreactivity was virtually absent during the early em-
bryonic phases (data not shown), but it appeared around
embryonic day E20 (Fig. 6A and B) in a few tubules,
most likely collecting ducts, and increased gradually with
development until days P22 and P30 (Fig. 6G to J). Im-
munoreactivity was first apparent at the luminal side of
the ducts at prenatal day E20 and postnatal days P1 and
P5 (Fig. 6A to D). Thereafter, immunostaining spread
all over the tubular cells and could be observed on both
the apical and the basolateral side, as well as in the cy-
tosol (Fig. 6J). Whereas mature or immature glomeruli,
proximal tubules, and the subcapsular mesenchyme were
essentially free of immunostaining; controls using the cor-
responding preimmune serum failed to produce specific
staining (data not shown).
DISCUSSION
Several authors have tried to identify the precise
nephron segments in which the V2R protein sites in the
kidney. With the exception of collecting ducts, the techni-
cal approaches used previously have failed to reveal the
exact cellular and subcellular distribution of the V2R in
this organ. Concerning these difficulties, one of the ini-
tial aims of our work was to raise and fully characterize
a novel antiserum directed toward a peptide of 25 amino
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Fig. 3. Immunoreactive V2R protein in the
adult rat kidney. Immunostaining was done on
5-lm tissue sections prepared from periodate-
lysine-paraformaldehyde fixed renal tissue.
Bound anti-peptide antibody to TLD25
(AS382; 1:200) was probed by the biotin-
streptoavidin peroxidase technique. (A) Im-
munoreactive V2R is shown in collecting
ducts (CD) of medullary rays and in distal
tubules (DCT). Panels (E and F) are higher
magnifications of distal convoluted tubules
(DCT) and collecting ducts (CD), respec-
tively. Arrows point to immunoreactive V2R
expressed on basolateral infoldings of distal
tubules (E) and collecting ducts (F). TAL,
thick ascending limb; G, glomerulus (D). Con-
trol where tissue had been incubated with the
preimmune serum (B) or with anti-TLD25 in
the presence of a 100 lg/mL of peptide TLD25
(C). Magnification ×100 (A, B); ×300 (C);
×700 (D), ×1000 (E). The figure is represen-
tative of 3 independent experiments.
acid residues in length of the predicted rat V2R sequence.
Our experiments carried out on native and recombinant
receptor clearly demonstrated that this antiserum specif-
ically identifies V2R. Furthermore, using different cell
lines known to express a single type of vasopressin re-
ceptor, and cell membranes prepared from rat kidney
and liver, we have shown that our antiserum does not
cross-react with the vasopressin V1R. Finally, our results
indicate that this antiserum is a useful probe for immuno-
cytochemical studies as well as for Western blot analysis.
We found that the antiserum showed, in membranes
from cells transfected with the V2R-GFP fusion protein,
immunoreactive bands of 60, 75, and 120 kD. The two
lower molecular bands seem to represent different gly-
cosylation stages of the fusion protein, whereas the high
molecular mass band appears to be an oligomeric form
of V2R [16, 17]. Based on these studies and on our results
with the tunicamycin-treated cells, we tentatively assign
the 75 kD fusion protein having a complex-type of gly-
cosylation, whereas the 60 kD form may represent the
high-mannose type of fusion protein. These results are
in good agreement with previous observations on human
and mouse V2R receptors expressed as GFP fusion pro-
teins [19–21]. Endo H digestion of the wild-type receptor
from rat kidney membranes clearly favors this notion,
suggesting that the fully glycosylated receptor is of 55 kD
(monomer) and 110 kD (dimer), the partially processed
high-mannose form is of 50 kD, whereas the unglycosy-
lated form is of 40 kD, and the additional band of 45 kD,
most likely representing an intermediate form. Alterna-
tively, some of these bands may also represent proteolytic
degradation products of V2R; we have not further ad-
dressed this possibility. The Endo H–induced loss of an
apparent mass of 15 kD is consistent with the presence of
two N-glycosylation sites [3]. Again, these data are com-
patible with previous reports on HA-tagged human V2R
[16, 17] and rat kidney V2R [22, 23].
One previous study using immunofluorescence de-
tected immunoreactive V2R in the collecting duct and
in the thick ascending limb of Henle [24]. PCR-based
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TAL
DCT
CNT
CD
Fig. 4. Identification of nephron segments expressing theV2R by colocalization with known tubular markers. Anti-TLD25 (AS382) (right panel)
and either anti-Tamm-Horsfall protein (THP) or Na/Cl cotransporter (NCCT) or anti-kallikrein (KALL) or aquaporin-2 (AQP2) were applied to
consecutive kidney sections. TAL, thick ascending limb; DCT, distal convulated tubules; CNT, connecting tubules; CD, collecting ducts. The figures
are representative of 5 independent immunostainings.
studies of microdissected nephron segments have largely
confirmed V2R mRNA expression in cortical and
medullary collecting ducts, whereas small signals were
detected in thick ascending limbs [7, 25]. However, two
major questions have not been fully addressed yet: (1)
is the V2R present in other tubules of the distal nephron
such as distal convoluted and connecting tubules? and (2)
what is the differential distribution of V2R between the
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Fig. 5. Ontogeny of V2R probed by quantitative RT-PCR. (A) PCRs
were carried out for the indicated cycles and a sample was analyzed by
agarose gel electrophoresis and quantified. The number of cycles was
plotted against relative intensity of bands of both V2R (•) and GAPDH
(◦) cDNAs. The following PCR experiments were performed at 30 cy-
cles. (B) Relative levels of V2R mRNA were followed by noncompet-
itive RT-PCR from day 18 of the embryonic period (E18) to postna-
tal day 120 (P120). Left lane, DNA molecular size ladder; GAPDH,
glyceraldehydes-3-phosphate dehydrogenase. (C) Ratio of V2R and
GAPDH transcripts measured by quantitative densitometry. Results
represent mean ± SE (N = 3).
apical and basolateral faces of tubular cells? Using our
anti-peptide probe we demonstrated the expression of
V2R in the distal convoluted tubules and in the connect-
ing tubules and in cortical, outer, and inner medullary
collecting ducts, as well as in thick ascending limbs of
E 20
P 1
P 5
P 22
P 30
Fig. 6. Ontogeny of V2R probed by immunohistochemistry. Tissue sec-
tions prepared from periodate-lysine-paraformaldehyde–fixed renal tis-
sue were incubated with anti-TLD25 (AS382; 1:200), and bound anti-
body was probed with the biotin-streptoavidin technique. Arrows point
to immunoreactive V2R expressed on basolateral infoldings of distal
nephron tubules. E, embryonic period; P, postnatal period. Magnifi-
cation, ×700. Each photograph is a representative of 4 independent
experiments.
Henle of the adult rat kidney. We have further substanti-
ated these findings by using specific tubular markers for
each of these segments. Interestingly, the distribution pat-
tern of V2R in connecting and collecting ducts overlaps
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with that of aquaporin-2 [25, 26], indicating that connect-
ing tubules and collecting ducts may represent the major
sites for water reabsorption in the rat nephron. On the
other hand, the presence of V2R in thick ascending limbs
may be associated with Na+ reabsorption because AVP
stimulates NaCl transport and also up-regulates the ex-
pression of the Na+/K+/2Cl− cotransporter; this effect
can be mimicked by the V2R-selective agonist, dDAVP
[27, 28].
Controversial findings have been reported for the dif-
ferential distribution of V2R between the various faces
of polarized cells. Using immunofluorescence techniques
and antibodies to the receptor, Nonoguchi et al have
found immunoreactive V2R protein both on apical and
basolateral domains of terminal inner medullary collect-
ing duct cells [24], whereas others, using V2R fused to
tags, found it localized to the basolateral face of MDCK
cells [29, 30]. We found that our anti-peptide antibody
identified immunoreactive V2R to both the apical and
the basolateral face of tubular cells. During renal devel-
opment, this differential topologic distribution is subject
to change: between E20 and P3, V2R is found exclusively
at the apical side of tubular cells, whereas from P5 on,
immunoreactive V2R protein is also found at the baso-
lateral domain of these cells, where its relative staining
intensity increases over the next 45 days. In the adult
rat kidney, immunoreactive V2R at the basolateral mem-
brane clearly dominates over that at the apical face of
cells furnishing the distal nephron tubules and collecting
ducts. Differential staining is not due to a crossreactivity
of our antiserum with V1R because it failed to recognize
this vasopressin receptor subtype either on the surface of
rat aortic A10 cells or on rat liver membranes. Interest-
ingly, a fairly good immunoreaction was also found in the
cytoplasm of tubular cells. Furthermore, similar cellular
distribution displays the rat GFP-tagged V2R when it is
expressed in a heterologous system [18]. On the other
hand, it has been shown that the murine V2R is trans-
ported the cell surface slower than the human receptor.
Therefore, it seems likely that this distribution might be
due to a slow rate of transport of the receptor to the cell
surface.
Our study investigates, for the first time, the expres-
sion of V2R protein during kidney development. The re-
sults obtained with our antibody and those achieved by
RT-PCR showed a close correlation, though the PCR may
provide a more sensitive tool because it revealed V2R ex-
pression at day E18, whereas the immunoprobing did not
detect V2R before day E20. Using in situ hybridization
and radioligands to spot V2R binding sites, Ostrowski
et al [8] have come to similar conclusions as those ob-
tained with RT-PCR in this study. Our results are also
consistent with reports about the development of bind-
ing sites for [3H]AVP in the kidney [31, 32]. It is inter-
esting to note that AVP binding sites have been found
earliest on embryonic day E19 [9], and that the V2R ap-
pearance slightly precedes the onset of adenylate cyclase
responsiveness in these cells. Our results indicate that
renal V2R up-regulation is a perinatal event and, thus,
precedes the development of the urine-concentrating ca-
pacity of the kidney, which matures 2 to 4 weeks after
birth (P14 to P28) [33, 34]. Functional V2 receptors have
been found as early as on P2, and their level rises con-
tinuously until P14. Nevertheless, the precise functional
role of V2R up-regulation during nephron maturation
is not entirely clear. The absence of V2R in undiffer-
entiated mesenchyme and in the S-shaped body indi-
cates that AVP may not participate in the early stages of
nephron differentiation. Similar conclusions have been
drawn for the closely related bradykinin B2 receptor and
its functional role during renal ontogeny in the rat [14].
Application of specific V2R antagonists during rat kidney
development should shed novel light on the functional
significance of V2R in renal ontogeny. In this context, it
is worth mentioning that the exogenous administration of
AVP to neonatal rats at days P1 to P7 impairs the urine-
concentrating capacity of the adult kidney in response to
stimulation with AVP due to a reduction in vasopressin-
induced cyclic AMP production [35]. In addition, long-
term treatment for 13 weeks of growing lambs with the
V2 agonist dDAVP results in morphologic changes of
the kidney, mainly reflected by an increase in the size of
the outer medulla [36]. These reports indicate that during
kidney maturation, vasopressin receptors are fully func-
tional, and they might play a crucial role in renal devel-
opment.
CONCLUSION
Clearly, more sophisticated analyses are needed be-
fore we fully understand the functional implications of
differential localization and expression of V2R in renal
ontogeny and (patho)physiology.
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